---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-23-000010"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:47:18.396748+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech reports FY2022 net loss $140M; B-VEC PDUFA date May 19, 2023

## Summary
- Cash, cash equivalents and investments $383.8M at Dec 31, 2022.
- Net loss $140.0M for FY2022 vs $69.6M in FY2021; diluted EPS $(5.49) vs $(3.13).
- B-VEC PDUFA date set for May 19, 2023; all FDA inspections complete.
- Phase 3 GEM-3 trial results for B-VEC published in New England Journal of Medicine.
- Plans to initiate four pipeline trials in 2023 across dermatology, respiratory, aesthetics.

## SEC filing metadata
- accession: 0001711279-23-000010
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000010/0001711279-23-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000010/krys-20230227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-23-000010
- JSON: https://secwatch.observer/filing/0001711279-23-000010.json
- Plain text: https://secwatch.observer/filing/0001711279-23-000010.txt

## Key facts
- Earnings Releases
  Krystal Biotech, Inc. reported the fourth quarter ended December 31, 2022 results: net income $32.1 million, EPS $(1.25).
  - Period: the fourth quarter ended December 31, 2022
  - Net income: $32.1 million
  - EPS: $(1.25)
  - Result: reported results
  source text: Net losses for the quarters ended December 31, 2022 and 2021 were $32.1 million and $21.8 million, or $(1.25) and $(0.94) respectively, per common share (basic and diluted).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000010/0001711279-23-000010-index.htm
- Earnings Releases
  Krystal Biotech, Inc. reported the year ended December 31, 2022 results: net income $140.0 million, EPS $(5.49).
  - Period: the year ended December 31, 2022
  - Net income: $140.0 million
  - EPS: $(5.49)
  - Result: reported results
  source text: Net losses for the years ended December 31, 2022 and 2021 were $140.0 million and $69.6 million, or $(5.49) and $(3.13), respectively, per common share (basic and diluted).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000010/0001711279-23-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.